- Home
- APLM vs LRHC Comparison
APLM vs LRHC Comparison
Compare APLM & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- LRHC
- Stock Information
- Founded
- APLM 2016
- LRHC 2004
- Country
- APLM United States
- LRHC United States
- Employees
- APLM N/A
- LRHC N/A
- Industry
- APLM Blank Checks
- LRHC
- Sector
- APLM Finance
- LRHC
- Exchange
- APLM Nasdaq
- LRHC Nasdaq
- Market Cap
- APLM 6.1M
- LRHC 5.6M
- IPO Year
- APLM N/A
- LRHC 2023
- Fundamental
- Price
- APLM $5.80
- LRHC $5.77
- Analyst Decision
- APLM
- LRHC
- Analyst Count
- APLM 0
- LRHC 0
- Target Price
- APLM N/A
- LRHC N/A
- AVG Volume (30 Days)
- APLM 47.7K
- LRHC 353.8K
- Earning Date
- APLM 08-18-2025
- LRHC 08-26-2025
- Dividend Yield
- APLM N/A
- LRHC N/A
- EPS Growth
- APLM N/A
- LRHC N/A
- EPS
- APLM N/A
- LRHC N/A
- Revenue
- APLM $198,000.00
- LRHC $73,874,281.00
- Revenue This Year
- APLM $415.15
- LRHC N/A
- Revenue Next Year
- APLM N/A
- LRHC N/A
- P/E Ratio
- APLM N/A
- LRHC N/A
- Revenue Growth
- APLM N/A
- LRHC 90.36
- 52 Week Low
- APLM $4.47
- LRHC $4.33
- 52 Week High
- APLM $35.98
- LRHC $142.40
- Technical
- Relative Strength Index (RSI)
- APLM 47.28
- LRHC 42.16
- Support Level
- APLM $5.41
- LRHC $4.89
- Resistance Level
- APLM $6.38
- LRHC $5.60
- Average True Range (ATR)
- APLM 0.44
- LRHC 0.64
- MACD
- APLM -0.01
- LRHC 0.12
- Stochastic Oscillator
- APLM 31.20
- LRHC 38.20
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.